Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Sep. 30, 2011	Oct. 01, 2010
Cash flows from operating activities:
Net loss	$ (236,000)	$ (671,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation	529,000	475,000
Amortization	684,000	814,000
Stock based compensation expense	245,000	74,000
Change in fair value of warrant liability	(634,000)	89,000
Changes in operating assets and liabilities:
Accounts receivable - net	(916,000)	(736,000)
Inventories	108,000	(777,000)
Prepaid expenses and other assets	(28,000)	(235,000)
Accounts payable and accrued expenses	(274,000)	1,611,000
Net cash provided by (used in) operating activities	(522,000)	644,000
Cash flows from investing activities:
Capital expenditures	(406,000)	(449,000)
Change in restricted cash	500,000
Patent expenditures	(102,000)	(156,000)
Net cash used in investing activities	(8,000)	(605,000)
Cash flows from financing activities:
Net proceeds (payments) on bank term loan	312,000	(253,000)
Payments on MEDC/MSF term loan	(253,000)	(38,000)
Payments on related parties debt	(450,000)
Proceeds from exercise of restricted shares		1,000
Proceeds from exercise of stock options	25,000
Net cash used in financing activities	(366,000)	(290,000)
Net decrease in cash and cash equivalents	(896,000)	(251,000)
Cash and cash equivalents at beginning of period	4,744,000	1,762,000
Cash and cash equivalents at end of period	3,848,000	1,511,000
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	98,000	138,000
Non-cash financing activities:
Conversion of accrued MEDC loan interest to common stock		$ 562,000